Indian Journal of Pharmacology Home 

CLINICAL RESEARCH ARTICLES
[View FULLTEXT] [Download PDF]
Year : 2020  |  Volume : 52  |  Issue : 5  |  Page : 378--382

Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy

Vivek Kumar Garg1, Manoj Kumar Goyal1, Madhu Khullar2, Biman Saikia3, Bikash Medhi4, Ajay Prakash4, Nandita Prabhat1, Naresh Tandyala1, Karthik Vinay Mahesh1, Parampreet S Kharbanda1, Sudesh Prabhakar1, Manish Modi1, Vivek Lal1, Ritu Shree1, Julie Sachdeva1 
1 Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
4 Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Correspondence Address:
Dr. Julie Sachdeva
Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India

OBJECTIVES: The objectives of this study were to determine the relationship between genetic polymorphisms in gene encodings for CYP3A4 and carbamazepine (CBZ)-induced dose-related side effects in North Indian people with epilepsy. PATIENTS AND METHODS: The current prospective study included 37 patients with CBZ-induced dose-related side effects and 102 patients who did not experience side effects while on CBZ. The genotyping for CYP3A4 allele (CYP3A4*16) was done using real-time polymerase chain reaction (RT-PCR) in Applied Biosystems 7500 RT-PCR System (USA). CBZ was administered in all patients at a dose varying from 15 to 20 mg/kg daily. RESULTS: Various demographic variables were comparable between the groups except that control of seizures was far better in controls. After testing, it was found that none of our patients had the presence of CYP3A4*16 allele. CONCLUSION: CYP3A4*16 allele is not represented significantly in North Indian people with CBZ-induced dose-related side effects.


How to cite this article:
Garg VK, Goyal MK, Khullar M, Saikia B, Medhi B, Prakash A, Prabhat N, Tandyala N, Mahesh KV, Kharbanda PS, Prabhakar S, Modi M, Lal V, Shree R, Sachdeva J. Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy.Indian J Pharmacol 2020;52:378-382


How to cite this URL:
Garg VK, Goyal MK, Khullar M, Saikia B, Medhi B, Prakash A, Prabhat N, Tandyala N, Mahesh KV, Kharbanda PS, Prabhakar S, Modi M, Lal V, Shree R, Sachdeva J. Presence of allele CYP3A4*16 does not have any bearing on carbamazepine-induced adverse drug reactions in North Indian people with epilepsy. Indian J Pharmacol [serial online] 2020 [cited 2022 Jul 6 ];52:378-382
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2020;volume=52;issue=5;spage=378;epage=382;aulast=Garg;type=0